Qiagen NV said the U.S. Food and Drug Administration granted 510(k) clearance to its molecular diagnostic system QIAstat-Dx.

The Netherlands-based company developed QIAstat-Dx syndromic testing system to detect and identify multiple respiratory viral and bacterial pathogens.

Qiagen launched the QIAstat-Dx syndromic testing system together with its multiplex QIAstat-Dx respiratory panel.